REGARD
Regimen
- Experimental
- ramucirumab 8 mg/kg Q2W + BSC
- Control
- placebo + BSC
Population
Advanced gastric/GEJ adenocarcinoma after first-line platinum/fluoropyrimidine
Key finding
mOS 5.2 vs 3.8 mo (HR 0.776, 95% CI 0.603-0.998, p=0.047); mPFS 2.1 vs 1.3 mo (HR 0.483, p<0.0001)
Source: PMID 24094768
Timeline
Guideline citations
- NCCN GASTRIC (p.3)
- CSCO GASTRIC 2025 (p.103)⚠️ OCR source